Pulse Biosciences, Inc. (NASDAQ: PLSE) entered into an equity distribution agreement with Mizuho Securities USA LLC on September 15, 2026, allowing the company to sell up to $85,000,000 in common stock through at-the-market offerings on the Nasdaq Capital Market.

Under the agreement, Mizuho will act as sales agent and receive a commission of up to 3.0% of the gross sales price of any shares sold. The company is not obligated to sell any shares and may suspend solicitations at any time.

The new agreement follows a prior equity distribution agreement the company entered into with Mizuho on August 6, 2026, which allowed for the sale of up to $75,000,000 in common stock. As of September 14, 2026, the company had sold 1,379,925 shares under that earlier agreement, raising approximately $68.8 million.

Shares offered under the new agreement will be issued pursuant to a registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission on February 19, 2026, and declared effective February 27, 2026. The company filed a prospectus supplement with the SEC on September 15, 2026 in connection with the new offering.